4 Austin-area hospitals make Newsweek's list of top 400 in U.S.
Newsweek and global data platform Statista have ranked the world's top hospitals for 2025.
No Austin-area hospital made that top world list, but we did have four that were recognized as among the top hospitals in the United States:
St. David's Medical Center at No. 144
Baylor Scott & White Medical Center - Round Rock at No. 181
Ascension Seton Medical Center at No. 310
Ascension Seton Hays Medical Center in Kyle at No. 400
The Mayo Clinic in Rochester, Minnesota, ranked No. 1 for the United States and the world. No. 2 in the world was the Cleveland Clinic in Ohio, and No. 3 was Toronto General in Canada.
Only two Texas hospitals made that top 250 in the world list: Houston Methodist Hospital was No. 72, and UT Southwestern Medical Center in Dallas was No. 240.
The list of the top 250 hospitals is compiled after ranking the best hospitals in 30 countries.
In compiling its rankings, Newsweek and Statista surveyed medical experts, looked at patient data, hospital metrics and the Patient-Reported Outcome Measures survey.
This article originally appeared on Austin American-Statesman: 4 Austin-area hospitals make Newsweek's best hospitals in US list
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
an hour ago
- Associated Press
Blue Sky Scrubs Celebrates World Environment Day With Commitment to Sustainability and Innovation in Medical Apparel
Austin, TX - June 9, 2025 - Blue Sky Scrubs, a trailblazer in stylish and functional medical apparel, proudly joins the global community in celebrating World Environment Day 2025, reaffirming its dedication to sustainability, environmental responsibility, and conscious innovation. As a Texas-based company serving healthcare professionals nationwide, Blue Sky Scrubs is using this moment to highlight its eco-friendly initiatives and share its vision for a greener future in the healthcare industry. World Environment Day, led by the United Nations Environment Programme (UNEP), is celebrated every year on June 5 to encourage awareness and action for the protection of the environment. This year's theme, 'Our Land. Our Future. We are #GenerationRestoration,' underscores the urgent need to restore damaged ecosystems, combat desertification, and promote sustainable land management practices. Blue Sky Scrubs embraces this call by focusing on sustainability throughout its supply chain and product lifecycle. 'At Blue Sky Scrubs, we believe that healthcare doesn't stop at the hospital doors—it extends to how we care for the planet we all share,' said David Marquardt, Founder and CEO of Blue Sky Scrubs. 'We are proud to integrate environmentally conscious practices into our products and operations, and World Environment Day is a perfect occasion to reaffirm our commitment.' Sustainable Fabrics and Manufacturing From the beginning, Blue Sky Scrubs has prioritized high-quality, long-lasting materials that reduce the need for frequent replacement, ultimately minimizing waste. Over the past year, the company has expanded its eco-fabric collection, featuring blends made from recycled polyester, organic cotton, and sustainably harvested bamboo fibers. These materials are not only soft and breathable but also significantly reduce the environmental footprint associated with conventional textile production. The company has also partnered with low-impact dyeing facilities that use less water and produce less waste. Compared to traditional dyeing processes, this method reduces water consumption by up to 60% and energy usage by 40%, aligning with Blue Sky's goal of reducing its overall carbon emissions. Eco-Conscious Packaging As part of its sustainability overhaul, Blue Sky Scrubs recently transitioned to fully recyclable and biodegradable packaging. All online orders now arrive in recycled kraft mailers or compostable bags, sealed with water-based adhesives and printed using soy-based ink. Even the tags attached to Blue Sky products are made from post-consumer paper and are fully recyclable. This packaging shift has resulted in a 60% reduction in plastic waste from customer orders since 2023—a tangible impact that resonates with the company's environmentally-minded customers. 'It's not just about what we make, but how we deliver it,' said Angela Nguyen, Director of Product Development. 'Our customers care about the planet, and we're proud to support their values through every aspect of our business.' Green Office and Local Initiatives Blue Sky Scrubs has implemented a variety of green practices at its Austin headquarters, including a paperless office initiative, a comprehensive recycling program, energy-efficient lighting, and on-site composting. The company also offsets a portion of its energy use through the purchase of renewable energy credits from Texas-based wind farms. This World Environment Day, Blue Sky employees participated in a community tree planting event in partnership with TreeFolks, an Austin nonprofit dedicated to reforestation and urban greening. Over 100 native trees were planted along a stretch of greenbelt near South Austin, enhancing biodiversity and contributing to the city's heat mitigation efforts. 'We are proud to be an Austin-grown brand, and we want to be a good neighbor,' said Marquardt. 'Supporting our local environment is part of how we give back.' Education and Empowerment As part of its ongoing commitment to transparency and education, Blue Sky Scrubs launched a new digital series titled 'Scrubs With a Conscience' earlier this year. The blog and video series explore sustainability topics in the healthcare apparel industry, spotlight eco-conscious materials, and provide tips for healthcare professionals looking to reduce their environmental impact—both at work and at home. The company also released its first Annual Sustainability Report this month, which outlines progress on key environmental metrics, including reductions in water usage, energy consumption, packaging waste, and emissions. Available online, the report is part of Blue Sky's effort to hold itself accountable while inspiring others in the industry to follow suit. Looking Ahead: Circular Fashion Goals Blue Sky Scrubs is already looking to the future with plans to expand its garment recycling program, allowing customers to return used scrubs for responsible recycling or repurposing. The initiative, currently in pilot stage, aims to divert textile waste from landfills and explore opportunities for closed-loop manufacturing. Additionally, the company is investing in design for durability, creating apparel with modular components and reinforced seams that extend product life. These forward-thinking designs will be a core part of Blue Sky's upcoming 2026 Sustainable Essentials Collection, which is slated for launch later this year. 'Our goal is to be a leader not just in style and comfort, but in environmental responsibility,' said Nguyen. 'Every scrub we create should contribute to a healthier planet as well as a healthier patient.' A Shared Responsibility World Environment Day serves as a vital reminder that collective action is key to solving the planet's greatest environmental challenges. Blue Sky Scrubs invites healthcare workers, business leaders, and customers alike to reflect on how everyday choices—from what we wear to how we work—can contribute to a more sustainable future. 'We're proud of the steps we've taken,' Marquardt concluded, 'but there's always more to do. Blue Sky Scrubs is committed to walking this path—thoughtfully, responsibly, and side by side with our community.' To learn more about Blue Sky Scrubs' sustainability initiatives, visit or follow the conversation on social media using #BlueSkyGreen and #GenerationRestoration. Media Contact Company Name: Blue Sky Scrubs Contact Person: Azu Aguilera Email: Send Email Phone: 888-302-5837 Address:2209 Donely Dr. City: Austin State: Texas Country: United States Website: Press Release Distributed by To view the original version on ABNewswire visit: Blue Sky Scrubs Celebrates World Environment Day With Commitment to Sustainability and Innovation in Medical Apparel
Yahoo
3 hours ago
- Yahoo
Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia
NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it has received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for AXS-14 (esreboxetine) for the management of fibromyalgia. The FDA states that upon preliminary review, it found that the NDA was not sufficiently complete to permit a substantive review. Specifically, the FDA does not consider the second of the two placebo-controlled trials in the submission to be adequate and well-controlled because its primary endpoint was at 8 weeks and it used a flexible-dose paradigm. The FDA indicated that the first of the two placebo-controlled trials in the submission, which utilized a 12-week endpoint and a fixed-dose paradigm, is adequate and well-controlled. The FDA did not raise any questions relating to the positive results of the studies, both of which met their primary endpoints. To address the FDA's feedback, Axsome will conduct an additional controlled trial, which will use a fixed-dose paradigm and a 12-week primary endpoint as requested by the FDA. Axsome anticipates initiating this trial in the fourth quarter of 2025. 'The clear feedback provided by the FDA's Division of Anesthesiology, Addiction Medicine, and Pain Medicine allows us to move expeditiously with the continued development of this important investigational medicine for the approximately 17 million patients in the U.S. living with fibromyalgia. We are well positioned to initiate a new controlled trial that will incorporate the FDA's feedback by the end of 2025,' said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. 'As highlighted in the FDA's Patient-Focused Drug Development Initiative report The Voice of the Patient: Fibromyalgia, patients with fibromyalgia experience debilitating widespread pain, fatigue, and functional impairment, and report living with constant stigmatization, anxiety, depression, and fear of ongoing or worsening symptoms. We are excited and motivated by the potential for AXS-14 to address this high unmet medical need for patients, as evidenced by the consistent efficacy demonstrated to date across a broad range of fibromyalgia symptoms, including significant improvements in pain, function, and fatigue, in the completed trials.' About AXS-14 AXS-14 (esreboxetine) is a highly selective and potent norepinephrine reuptake inhibitor for the management of fibromyalgia and other conditions. Esreboxetine, the SS-enantiomer of reboxetine, is more potent and selective than racemic reboxetine. AXS-14 is an investigational drug product not approved by the FDA. About Fibromyalgia Fibromyalgia is a chronic debilitating disorder characterized by widespread pain, fatigue, disturbed sleep, depression, and cognitive impairment.1 Other symptoms of this disorder can include tingling in the hands and feet and headaches.1 Fibromyalgia has considerable detrimental effects on physical, emotional, social, and day-to-day functioning.1 Fibromyalgia is considered to be mediated mainly in the central nervous system. Approximately 17 million Americans, 90% of whom are women, are estimated to suffer from fibromyalgia.2 Treatment options for fibromyalgia are limited with only three pharmacologic treatments currently approved by the FDA. About Axsome Therapeutics Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain's biggest problems so patients and their loved ones can flourish. For more information, please visit us at and follow us on LinkedIn and X. Forward Looking Statements Certain matters discussed in this press release are 'forward-looking statements'. The Company may, in some cases, use terms such as 'predicts,' 'believes,' 'potential,' 'continue,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'intends,' 'may,' 'could,' 'might,' 'will,' 'should' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company's statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company's SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company's efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company's ability to maintain and expand payer coverage; the success, timing and cost of the Company's ongoing clinical trials and anticipated clinical trials for the Company's current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company's ability to fully fund the Company's disclosed clinical trials, which assumes no material changes to the Company's currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company's ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application ('NDA') for any of the Company's current product candidates; the Company's ability to fund additional clinical trials to continue the advancement of the Company's product candidates; the timing of and the Company's ability to obtain and maintain U.S. Food and Drug Administration ('FDA') or other regulatory authority approval of, or other action with respect to, the Company's product candidates, including statements regarding the timing of any NDA submission; the Company's ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company's ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company's research and development programs and collaborations; the success of the Company's license agreements; the acceptance by the market of the Company's products and product candidates, if approved; the Company's anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company's commercial launch of its other product candidates, if approved, and the potential impact on the Company's anticipated cash runway; the Company's ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Investors:Mark JacobsonChief Operating Officer(212) 332-3243mjacobson@ Media:Darren OplandDirector, Corporate Communications(929) 837-1065dopland@ References: Matthew J. Bair, Erin E. Krebs. Fibromyalgia. Ann Intern Med. 2020;172:ITC33-ITC48. doi:10.7326/AITC202003030 Vincent A, et al. Prevalence of fibromyalgia: a population-based study in Olmsted County, Minnesota, utilizing the Rochester Epidemiology Project. Arthritis Care Res (Hoboken). 2013 May;65(5):786-92. doi: 10.1002/ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Newsweek
6 hours ago
- Newsweek
Nurses Were Covid Heroes. Now They're Being Squeezed by Medicaid Cuts
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. New York City nurses are calling for reforms as an industry plagued by a "broken" health care system threatens their livelihoods and the future of their profession. Why It Matters Nurses were considered vital and lauded as heroes during the COVID-19 pandemic, when at the outset the National Institutes of Health highlighting their "critical roles and responsibilities" that included front-line patient care in hospitals; ensuring personalized, high-quality services irrespective of infectious conditions; and engaging in planning for outbreaks stemming from coronavirus-related outbreaks that could overwhelm health systems. "These are issues that have preceded the pandemic and will continue until hospitals make serious efforts to recruit and retain nurses and invest in safe patient care," Nancy Hagans, president of the New York State Nurses Association (NYSNA), told Newsweek. "We're also witnessing the effects of a broken healthcare system," she said. "Patients can't afford care, so they put it off, and they come into hospitals much sicker than they ever were. The looming Medicaid cuts will only make this worse. NYSNA nurses are trying to hold hospitals accountable and also do as much as possible on the policy front to expand access to care." What To Know Hagans said that she and other nurses have complained about a nursing shortage for years. "NYSNA nurses have always maintained that there are more than enough nurses, but hospitals refuse to make real efforts to recruit and retain nurses," Hagans said. "We are seeing many more grads entering the profession than nurses leaving. Through better working conditions, safe staffing, and pay and benefits that respect nurses, hospitals could address whatever staffing issues they create." However, NYSNA, New York's largest union and professional association for registered nurses, which represents over 42,000 nurses and health care professionals, has been vocal about recent actions by some hospital systems that are cutting costs as well as jobs. New York City nurses and organizations have warned for years that staffing reductions and dwindling budgets are negatively impacting the profession long-term. New York City nurses and organizations have warned for years that staffing reductions and dwindling budgets are negatively impacting the profession long-term. Photo-illustration by Newsweek/Getty/Canva Montefiore Moses and Weiler In February, dozens of Bronx nurses at Montefiore Moses and Weiler spoke out about purported overcrowding and minimized services in emergency departments and hospital floors, as well as some surgical and palliative care services. Montefiore recorded a 0.2 percent operating loss in the first quarter of 2025. The statement, provided to Newsweek, says that while finances remained consistent year over year, "the proposed changes to reimbursements for Medicare and Medicaid are drawing the attention of healthcare providers across the country." "As one of the largest employers and providers of healthcare in the Bronx and Westchester, we are navigating a challenging and uncertain healthcare environment," Montefiore officials said. "Yet, we remain committed to providing the highest quality care to our communities, and to evaluating opportunities to reduce expenses and diversify our payer mix. "We implore elected officials to continue partnering with institutions like ours, serving a patient population that is 85 percent covered by government payor, to ensure sustainable funding." NewYork-Presbyterian Hospital In May, the NYSNA criticized NewYork-Presbyterian Hospital, a nonprofit academic medical center in New York City, following the announcement of a 2 percent staffing cut across their system—calling it "outrageous and deeply offensive" due to NYP being the city's wealthiest hospital system and one of the country's most financially stable. "Given current macroeconomic realities and anticipated challenges ahead, we have made the difficult decision to reduce our workforce by approximately 2 percent," an NYP spokesperson told Newsweek. "Where possible, we are working diligently to identify new and similar roles for impacted team members. "To elaborate, the healthcare environment continues to evolve, including changes to Medicaid and cuts to research grants to our medical school partners. In addition to these external factors, we are seeing fewer inpatients than expected and incurring higher expenses than projected. Focusing on improving efficiencies and managing expenses is a prudent action that will enable us to continue our mission of providing excellent care for our patients and communities." Hagans said that hospitals like Presbyterian, "with hefty amounts of cash on hand and historic executive pay," should be doing all they can to maintain and expand care rather than cut it. Albany Medical Center On June 5, nurses at Albany Medical Center called out the hospital for its ongoing refusal to address the staffing crisis and protect patient care. The criticism was in response to the nurses providing an update on the hospital's responses to a State Department of Health (DOH) report that found more than 500 violations, including 480 relating to safe staffing standards and 24 procedural violations. The violations were found across 26 different units, including 32 specifically within the neonatal intensive care unit, according to NYSNA. Almost a year after its initial investigation, and following several rejected correction plans, the DOH has yet to issue fines or prompt substantive change from the hospital, according to NYSNA. They called on the Albany Med Board of Directors to hold the hospital accountable. Nearly a year after its first investigation and several rejected correction plans, the DOH has yet to issue fines or spur substantive change from the hospital. Roughly 1,000 nurses signed a petition calling on Albany Med to negotiate a fair contract that will help address the staffing crisis. "There have been no nursing cuts at Albany Medical Center," Sue Rajchel, spokesperson for Albany Med, told Newsweek. "That is why we welcomed 300 new nurses in 2024 and are committed to hiring 400 nurses in 2025. "Our workforce is our greatest asset. We are continuing to negotiate with the union in good faith. We remain confident that our most recent contract proposal, which includes robust wage increases and enhanced benefits, is strong and fair. We will continue to listen to our nurses and advocate for them as we always have." What People Are Saying Nancy Hagans, president of the New York State Nurses Association, told Newsweek: "Less nurses compromises care. Period. The recent layoffs at Presbyterian will affect children and vulnerable patients most dramatically. Presbyterian has said that the impacted services will continue at other campuses, but for many, traveling long distances for care puts that care out of reach." What Happens Next "For nurses who know these cuts will negatively impact their communities, it's extremely demoralizing. But NYSNA nurses will keep fighting," Hagans said.
